Table of Contents
Pharmacologic Stress Agents Market – Introduction
The global pharmacologic stress agents market is expected to grow at a fast pace during the forecast period 2017 to 2025. In the pharmacologic stress agents market report, the market is segmented based on drug type and region. Gout can be termed as a variant of arthritis and can either be acute or chronic. Pharmacologic stress agents are utilized for artificially inducing stress on the circulatory system during pharmacologic stress testing. Pharmacologic stress testing is performed to monitor a heart condition or to find problems related to the heart and then to devise a treatment plan based on the found problems. Problems to be identified include shortness of breath, chest pain, arrhythmia, and weakness, among others. The market for pharmacologic stress agents is primarily being driven by the growing number of patients with cardiovascular diseases globally.
Report Overview
| Aspect | Details |
|---|---|
| Base Year of Estimation | 2016 |
| Value Estimation Year | 2017 |
| Forecast Period | 2017 – 2025 |
| Market Segmentations | By Pharmacologic Agent Type, Applications, Regions |
| Regional Scope | North America, Asia Pacific, Europe, Middle East & Africa and Latin America |
| Report Coverage | Market Dynamics, Segmentation Overview and Competitive Landscape of the market |
How Is The Pharmacologic Stress Agents Market Segmented?
| By Term | Segments |
|---|---|
| By Pharmacologic Agent Type | Adenosine, Regadenosone, Dipyridamole and Dobutamine |
| By Applications | Nuclear Imaging, Echocardiogram, Magnetic Resonance Imaging, Computed Tomography Scan and Others |
| By Regions | North America, Asia Pacific, Europe, Middle East & Africa and Latin America |
Who Are The Leading Competitors In This Pharmacologic Stress Agents Market?
| Headquarters | Corporations |
|---|---|
| Japan | Astellas Pharma, Inc. |
| The U.S. | Gilead Sciences, Inc., Cardinal Health, Inc. |
| The U.K. | Rapidscan Pharma Solutions, Inc. |
What Are the Driving Factors for the Growth of Pharmacologic Stress Agents Market?
- Growing demand for different types of cardiovascular testing
- Unhealthy lifestyle and food habits leading to growing health problems, heart conditions and the healthcare professionals are using different types of testing procedure in detection
- Development in technology
Market Dynamics
As per the World Health Organization, 31% of global deaths, or the deaths of 7.4 million people approximately, were caused by cardiovascular diseases, in 2015. Additionally, of the 7.4 million deaths, 6.7 million deaths were due to strokes. Such a widespread prevalence of cardiovascular disease is leading to a growing demand for different types of cardiovascular testing. This, in turn, is fueling the expansion of the pharmacologic stress agents market.
The hectic and unhealthy lifestyles of people around the globe are leading to the development of several sorts of health problems and diseases, including diabetes mellitus. An unhealthy lifestyle leads to improper rest for the body and erratic food habits. Due to such growing health problems, heart conditions that were only found in people over 60 years of age are now being found in 30-year-old people also. Hence, healthcare providers are continuously engaging in different types of testing, to determine heart problems. This, in turn, has had a positive impact on the global growth of the market for pharmacologic stress agents.
The rising cost of pharmacologic stress agents, coupled with the cost of stress testing, is a restraining factor for the growth of the market. As per WHO, 82% of the 7.4 million cardiovascular disease-related deaths in 2015 were in low and middle income countries. This suggests the high prevalence rate of such diseases in these countries. Hence, the patient population is often unable to bear the high cost of pharmacologic stress testing, leading to growth restraint for the pharmacologic stress agent market. However, with the growing improvement in technology and due to the better results from these agents, such restraints are not expected to have a significant impact on the growth of the pharmacologic stress agents market during the forecast period.
Segmentation Overview
By pharmacologic agent type
By pharmacologic agent type, the global pharmacologic stress agents market is segmented into Adenosine, Regadenosone, Dipyridamole and Dobutamine. Adenosine and Regadenosone are two of the most popular stress agents and both function as coronary vasodilator, which increases coronary blood flow.
- Adenosine,
- Regadenosone,
- Dipyridamole, and
- Dobutamine
By application
On the basis of application, the global market for pharmacologic stress agents is segmented into nuclear imaging, echocardiogram (ECG), magnetic resonance imaging (MRI), Computed Tomography (CT) Scan and others.
- Nuclear Imaging,
- Echocardiogram,
- Magnetic Resonance Imaging,
- Computed Tomography Scan and Others
By geography
By geography, the market has been segmented into North America, Europe, Asia Pacific, Middle East & Africa (MEA),and Latin America. In terms of revenue, North Americaaccounted for the largest market share of the pharmacologic stress agents market, followed by Asia Pacific. The presence of large patient pool and advanced diagnostic centers are the primary growth driver for the North American market for pharmacologic stress agents.
- North America,
- Asia Pacific,
- Europe,
- Middle East & Africa, and
- Latin America
Competitive Landscape
Majorcompanies operating in the pharmacologic stress agents market are Astellas Pharma, Inc. (Japan), Gilead Sciences, Inc. (The U.S.), Rapidscan Pharma Solutions, Inc. (The U.K.), and Cardinal Health, Inc. (The U.S.) among others.
The latest news from the industry straight to your inbox.
Join 2,000+ subscribers for exclusive access to our monthly newsletter with market research data, industry news.
